SPRO Spero Therapeutics (SPRO) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001701108
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
39
13F, latest reported quarter
What the filings say about SPRO
Insiders, 180 days
-$63.4K net sold
1 seller · 0% of sales under a 10b5-1 plan
Spero Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Spero Therapeutics, Inc. insiders sold a net $63.4K of stock across 74 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Feb 6, 2026.
- The trade is 2.6% of the 986,851 shares held after it.
- No other insider sold within 30 days.
- 39 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Rajavelu Esther sold about $63.4K of SPRO on May 4, 2026; 39 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Feb 2, 2026.
- The trade is 3.5% of the 1,062,907 shares held after it.
- 1 other insider sold within 30 days.
- 39 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Rajavelu Esther sold about $87.6K of SPRO on Feb 6, 2026; 1 other insider sold within 30 days and 39 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Feb 2, 2026.
- The trade is 5.0% of the 1,012,091 shares held after it.
- 1 other insider sold within 30 days.
- 39 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Rajavelu Esther sold about $119.9K of SPRO on Feb 6, 2026, the largest insider sale at the company since 2022; 1 other insider sold within 30 days and 39 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Feb 4, 2026.
- The trade is 2.5% of the 742,506 shares held after it.
- 1 other insider sold within 30 days.
- 39 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Keutzer Timothy sold about $44.0K of SPRO on Feb 6, 2026; 1 other insider sold within 30 days and 39 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Feb 3, 2026.
- The trade is 0.5% of the 761,158 shares held after it.
- 1 other insider sold within 30 days.
- 39 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Keutzer Timothy sold about $7.8K of SPRO on Feb 4, 2026; 1 other insider sold within 30 days and 39 funds added in the latest 13F quarter.74 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$63.4K over 180 days
more than 57% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
39 funds bought in last quarter
below 58% of Pharma & Biotech
Revenue
+3292.5% year over year
more than 98% of Pharma & Biotech
Margin
68.1% net margin
more than 96% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.7% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 70% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SPRO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-51.4%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SPRO: institutional holders (13F)
13F holdings, latest reported quarter
9,190,606 sh
$20.3M
2,362,348 sh
$5.3M
2,036,226 sh
$4.5M
947,904 sh
$2.1M
889,979 sh
$2.0M
Congress trades in SPRO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SPRO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SPRO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$100.7K position · as of 2026-05-31
0.5%
ACUITAS US MICROCAP FUND
$124.8K position · as of 2026-06-30
0.1%
Ultra-Small Company Market Fund
$143.2K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$334.2K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$22.5K position · as of 2026-06-30
0.0%
Omni Small-Cap Value Fund
$110.5K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
5
Phase 1
0 active
1
Phase 2
0 active
1
Phase 3
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Health And Human Services
IGF::OT::IGF · 2018-07-12
$49.2M
Department Of Health And Human Services
TO ADVANCE CLINICAL AND NON-CLINICAL DEVELOPMENT OF AN ANTIBIOTIC CANDIDATE. · 2021-05-17
$10.5M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $63.4K sold by insiders over 180 days, 39 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SPRO financials
Revenue growth
+3292.5%
XBRL, annual
Net margin
68.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$47.0M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SPRO
| FY Dec 2025 | $66.8M |
| FY Dec 2024 | $48.0M |
| FY Dec 2023 | $103.8M |
| FY Dec 2022 | $53.5M |
| FY Dec 2021 | $18.3M |
| Jun 2026 | $0 |
| Mar 2026 | $258.0K |
| Dec 2025 | $41.3M |
| Sep 2025 | $5.4M |
| Jun 2025 | $14.2M |
| Mar 2025 | $5.9M |
| Dec 2024 | $15.0M |
| Sep 2024 | $13.5M |
At each fiscal year end
Single quarter
Net margin, TTM
+15.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SPRO
| FY Dec 2025 | +12.8% |
| FY Dec 2024 | -142.9% |
| FY Dec 2023 | +22.0% |
| FY Dec 2022 | -86.7% |
| FY Dec 2021 | -491.9% |
| Jun 2026 | n/a |
| Mar 2026 | -2,792% |
| Dec 2025 | +76.3% |
| Sep 2025 | -135.6% |
| Jun 2025 | -12.0% |
| Mar 2025 | -236.1% |
| Dec 2024 | -138.8% |
| Sep 2024 | -127.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM SPRO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity SPRO
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
215.16x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt SPRO
| FY Dec 2025 | -138.73x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -379.25x |
| FY Dec 2022 | -80.53x |
| FY Dec 2021 | -466.28x |
| Jun 2026 | 215.16x |
| Mar 2026 | 79.58x |
| Dec 2025 | -138.73x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -1,348.92x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+19.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SPRO
| FY Dec 2025 | +16.3% |
| FY Dec 2024 | -89.6% |
| FY Dec 2023 | +24.9% |
| FY Dec 2022 | -56.5% |
| FY Dec 2021 | -81.5% |
| Jun 2026 | +19.2% |
| Mar 2026 | +35.1% |
| Dec 2025 | +16.3% |
| Sep 2025 | -95.3% |
| Jun 2025 | -94.6% |
| Mar 2025 | -107.3% |
| Dec 2024 | -89.6% |
| Sep 2024 | +5.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+12.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SPRO
| FY Dec 2025 | +9.6% |
| FY Dec 2024 | -46.8% |
| FY Dec 2023 | +14.8% |
| FY Dec 2022 | -31.4% |
| FY Dec 2021 | -55.3% |
| Jun 2026 | +12.9% |
| Mar 2026 | +22.3% |
| Dec 2025 | +9.6% |
| Sep 2025 | -46.3% |
| Jun 2025 | -50.6% |
| Mar 2025 | -56.9% |
| Dec 2024 | -46.8% |
| Sep 2024 | +2.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital SPRO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+13.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SPRO
| FY Dec 2025 | +10.4% |
| FY Dec 2024 | -71.0% |
| FY Dec 2023 | +17.3% |
| FY Dec 2022 | -33.0% |
| FY Dec 2021 | -60.4% |
| Jun 2026 | +13.2% |
| Mar 2026 | +26.5% |
| Dec 2025 | +10.4% |
| Sep 2025 | -74.0% |
| Jun 2025 | -75.9% |
| Mar 2025 | -85.0% |
| Dec 2024 | -71.0% |
| Sep 2024 | -1.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
7.64x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing SPRO
| FY Dec 2025 | 15.53x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 3.42x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 15.79x |
| Mar 2026 | 8.67x |
| Dec 2025 | 15.53x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 16.75x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$11.6M
market value at close 2026-10-26 on 2026-08-07 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value SPRO
| FY Dec 2025 | $91.1M |
| FY Dec 2024 | $3.3M |
| FY Dec 2023 | $1.7M |
| FY Dec 2022 | -$19.4M |
| FY Dec 2021 | $405.1M |
| Jun 2026 | $77.3M |
| Mar 2026 | $79.4M |
| Dec 2025 | $91.1M |
| Sep 2025 | $57.2M |
| Jun 2025 | $130.9M |
| Mar 2025 | -$8.6M |
| Dec 2024 | $3.3M |
| Sep 2024 | -$3.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield SPRO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing SPRO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $66.8M | $48.0M | $103.8M | $53.5M |
| Operating income | $6.3M | -$73.4M | $21.5M | -$42.2M |
| Net income | $8.6M | -$68.6M | $22.8M | -$46.4M |
| EPS (diluted) | 0.15 | -1.27 | 0.43 | -1.23 |
| Operating cash flow | -$12.6M | -$23.4M | -$33.0M | -$7.7M |
| Cash | $40.3M | $52.9M | $76.3M | $109.1M |
| Long-term debt | $91.0K | $0 | $87.0K | $96.0K |
SEC XBRL, fiscal years, as known on 2026-10-28
SPRO Stock Sonar score 6/7 axes
Find similar shapesCompareSPRO ranks highest on growth (98th percentile) and financial health (92nd), and lowest on insider conviction (27th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SPRO filings, in plain words
Are Spero Therapeutics insiders buying or selling SPRO?
In the 180 days to 2026-10-28, Spero Therapeutics insiders were net sellers, a net $63.4K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Spero Therapeutics insiders were net sellers of SPRO, a net $63.4K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
